Editas Medicine, Inc. (0IFK.L)
USD 1.02
(0.22%)
USD 1.02
(0.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -153.21 Million USD | 25.02% |
| 2022 | -204.35 Million USD | -10.4% |
| 2021 | -185.1 Million USD | -69.18% |
| 2020 | -109.41 Million USD | 11.38% |
| 2019 | -123.46 Million USD | -12.29% |
| 2018 | -109.95 Million USD | 8.62% |
| 2017 | -120.32 Million USD | -23.81% |
| 2016 | -97.18 Million USD | -33.31% |
| 2015 | -72.9 Million USD | -432.7% |
| 2014 | -13.68 Million USD | -155.84% |
| 2013 | -5.34 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -61.95 Million USD | -228.23% |
| 2024 Q2 | -67.6 Million USD | -9.13% |
| 2024 Q3 | -62.14 Million USD | 8.08% |
| 2023 Q4 | -18.87 Million USD | 58.08% |
| 2023 FY | -153.21 Million USD | 25.02% |
| 2023 Q1 | -45.56 Million USD | 17.2% |
| 2023 Q2 | -40.29 Million USD | 11.58% |
| 2023 Q3 | -45.01 Million USD | -11.74% |
| 2022 Q2 | -52.67 Million USD | -4.76% |
| 2022 FY | -204.35 Million USD | -10.4% |
| 2022 Q1 | -50.28 Million USD | -21.34% |
| 2022 Q4 | -55.03 Million USD | -2.04% |
| 2022 Q3 | -53.93 Million USD | -2.39% |
| 2021 Q4 | -41.43 Million USD | -6.02% |
| 2021 Q1 | -56.72 Million USD | 9.23% |
| 2021 Q2 | -55.25 Million USD | 2.59% |
| 2021 Q3 | -39.08 Million USD | 29.27% |
| 2021 FY | -185.1 Million USD | -69.18% |
| 2020 Q1 | -37.72 Million USD | 0.12% |
| 2020 FY | -109.41 Million USD | 11.38% |
| 2020 Q4 | -62.49 Million USD | -899.32% |
| 2020 Q3 | 7.81 Million USD | 133.17% |
| 2020 Q2 | -23.57 Million USD | 37.51% |
| 2019 Q3 | -32.94 Million USD | 2.5% |
| 2019 FY | -123.46 Million USD | -12.29% |
| 2019 Q4 | -37.77 Million USD | -14.66% |
| 2019 Q2 | -33.78 Million USD | -15.51% |
| 2019 Q1 | -29.24 Million USD | -16.74% |
| 2018 Q3 | -15.23 Million USD | 60.65% |
| 2018 Q4 | -25.05 Million USD | -64.42% |
| 2018 FY | -109.95 Million USD | 8.62% |
| 2018 Q1 | -30.93 Million USD | 14.51% |
| 2018 Q2 | -38.72 Million USD | -25.16% |
| 2017 FY | -120.32 Million USD | -23.81% |
| 2017 Q1 | -31.09 Million USD | 21.03% |
| 2017 Q2 | -26.43 Million USD | 14.98% |
| 2017 Q3 | -26.59 Million USD | -0.61% |
| 2017 Q4 | -36.18 Million USD | -36.05% |
| 2016 Q4 | -39.37 Million USD | -87.33% |
| 2016 FY | -97.18 Million USD | -33.31% |
| 2016 Q3 | -21.02 Million USD | -10.39% |
| 2016 Q2 | -19.04 Million USD | -7.31% |
| 2016 Q1 | -17.74 Million USD | -40.47% |
| 2015 Q2 | -47.57 Million USD | -799.09% |
| 2015 Q3 | -7.4 Million USD | 84.43% |
| 2015 Q1 | -5.29 Million USD | 2.22% |
| 2015 Q4 | -12.63 Million USD | -70.6% |
| 2015 FY | -72.9 Million USD | -432.7% |
| 2014 FY | -13.68 Million USD | -155.84% |
| 2014 Q3 | -3.43 Million USD | -36.19% |
| 2014 Q4 | -5.41 Million USD | -57.39% |
| 2014 Q2 | -2.52 Million USD | 0.0% |
| 2014 Q1 | -2.52 Million USD | 0.0% |
| 2013 FY | -5.34 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 50.331% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 56.483% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -1.079% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 44.511% |
| bluebird bio, Inc. | -211.91 Million USD | 27.697% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -29.285% |
| Imunon, Inc. | -19.51 Million USD | -685.135% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 111.283% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 119.425% |
| Myriad Genetics, Inc. | -112 Million USD | -36.803% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 161.361% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 11742.781% |
| Verastem, Inc. | -87.36 Million USD | -75.374% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 98.226% |
| Waters Corporation | 642.23 Million USD | 123.857% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 102.556% |
| Biogen Inc. | 1.16 Billion USD | 113.196% |
| Nektar Therapeutics | -276.05 Million USD | 44.497% |
| Perrigo Company plc | -12.7 Million USD | -1106.449% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2298.169% |
| Illumina, Inc. | -1.16 Billion USD | 86.803% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -243.515% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 65.494% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -38.586% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -284.393% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 191.395% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 40.574% |
| Evolus, Inc. | -61.68 Million USD | -148.389% |
| Adicet Bio, Inc. | -142.65 Million USD | -7.403% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -73.166% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 103.875% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 26.776% |
| FibroGen, Inc. | -284.23 Million USD | 46.094% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 112.356% |
| OPKO Health, Inc. | -188.86 Million USD | 18.873% |
| Homology Medicines, Inc. | -53.74 Million USD | -185.096% |
| Geron Corporation | -184.12 Million USD | 16.786% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 65.197% |
| Exelixis, Inc. | 207.76 Million USD | 173.746% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -78.379% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -222.532% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 68.158% |
| Zoetis Inc. | 2.34 Billion USD | 106.537% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 35.955% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -182.754% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 104.233% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -263.087% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 58.17% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 71.413% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 244.356% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 154.411% |
| Blueprint Medicines Corporation | -506.98 Million USD | 69.778% |
| Insmed Incorporated | -749.56 Million USD | 79.559% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1309.115% |
| Incyte Corporation | 597.59 Million USD | 125.639% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 79.853% |